Hemolysis Detection Devices Market Report 2026

Hemolysis Detection Devices Market Overview

• Hemolysis Detection Devices market size has reached to $0.92 billion in 2025 • Expected to grow to $1.34 billion in 2030 at a compound annual growth rate (CAGR) of 7.7% • Growth Driver: Rising Clinical Trials Activity Driving The Market Growth Due To Increasing Demand For Accurate Blood Sample Analysis And Drug Safety Assessment • Market Trend: Advancements In Hemolysis Detection In Automated Point-Of-Care Blood Gas Analyzers Enhancing Diagnostic Accuracy • Asia-Pacific was the largest region and fastest growing region.

What Is Covered Under Hemolysis Detection Devices Market?

Hemolysis detection devices are specialized diagnostic systems used to detect and quantify the breakdown of red blood cells in blood specimens. They assess the presence of free hemoglobin released into plasma or serum through spectrophotometric, optical, or biochemical detection techniques. Hemolysis detection devices are primarily used to maintain blood sample quality in clinical laboratories, minimize the risk of erroneous test results, and aid in the early identification of hemolytic disorders or transfusion-related adverse events. The main product types of hemolysis detection devices include benchtop hemolysis detection devices, portable hemolysis detection devices, and automated hemolysis detection systems. Benchtop devices are laboratory-based solutions designed to provide accurate detection and quantification of hemolysis in blood samples. They utilize technologies such as spectrophotometry, colorimetry, Visual Inspection, and other technologies. The various applications involved are blood banks, hospitals, diagnostic laboratories, research institutes, and other applications, and are used by several end users, such as hospitals and clinics, blood centers, research and academic institutes, and other end users.

What Is The Hemolysis Detection Devices Market Growth Forecast?

The hemolysis detection devices market size is expected to see strong growth in the next few years. It will grow to $1.34 billion in 2030 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to growing demand for automated laboratory workflows, increasing investment in advanced diagnostic infrastructure, rising adoption of portable point of care devices, expansion of blood bank networks in emerging markets, increasing emphasis on early detection of transfusion related complications. Major trends in the forecast period include increasing adoption of automated hemolysis detection systems, rising demand for high throughput laboratory analyzers, growing integration of spectrophotometric detection technologies, expansion of point of care hemolysis testing, rising focus on blood sample quality control protocols.

Global Hemolysis Detection Devices Market Segmentation

1) By Product Type: Benchtop Hemolysis Detection Devices, Portable Hemolysis Detection Devices, Automated Hemolysis Detection Systems 2) By Technology: Spectrophotometry, Colorimetry, Visual Inspection, Other Technologies 3) By Application: Blood Banks, Hospitals, Diagnostic Laboratories, Research Institutes, Other Applications 4) By End-User: Hospitals And Clinics, Blood Centers, Research And Academic Institutes, Other End Users Subsegments: 1) By Benchtop Hemolysis Detection Devices: Single Sample Benchtop Hemolysis Analyzers, Multi Sample Benchtop Hemolysis Analyzers, Integrated Laboratory Benchtop Hemolysis Systems 2) By Portable Hemolysis Detection Devices: Handheld Hemolysis Detection Devices, Battery Operated Portable Hemolysis Analyzers, Point Of Care Portable Hemolysis Devices 3) By Automated Hemolysis Detection Systems: Fully Automated Hemolysis Detection Systems, Semi Automated Hemolysis Detection Systems, High Throughput Automated Hemolysis Analyzers

What Is The Driver Of The Hemolysis Detection Devices Market?

The growing clinical trials activity is expected to propel the growth of the hemolysis detection devices market going forward. Clinical trials activity refers to conducting research studies on humans to test the safety and efficacy of drugs or treatments, with headspace gas analysis ensuring product quality and stability during these trials. Clinical trial activity is increasing due to the rising demand for new and effective therapies, driven by the growing prevalence of chronic and lifestyle diseases, which require more clinical studies to evaluate innovative treatments safely. Hemolysis detection devices help clinical trial activity by rapidly identifying the breakdown of red blood cells in blood samples, ensuring sample integrity and reliable laboratory results, which are critical for accurate assessment of drug safety and efficacy. For instance, in December 2024, according to the Association of the British Pharmaceutical Industry (ABPI), a UK-based trade association, the number of industry clinical trials initiated in the UK increased to 426 in 2023, from 411 in 2022. Therefore, the growing clinical trials activity is driving the growth of the hemolysis detection devices industry.

Key Players In The Global Hemolysis Detection Devices Market

Major companies operating in the hemolysis detection devices market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Becton Dickinson Company, Mindray Bio Medical Electronics Co. Ltd., Sysmex Corporation, Bio Rad Laboratories Inc., Werfen S.A., HORIBA Medical SAS, Greiner Bio One International GmbH, Randox Laboratories Ltd., Agappe Diagnostics Ltd., Guangzhou Wondfo Biotech Co. Ltd., Radiometer Medical ApS, EKF Diagnostics Holdings plc, Hemcheck Sweden AB, Alta DiagnoTech Co. Ltd., Ortho Clinical Diagnostics Inc.

Global Hemolysis Detection Devices Market Trends and Insights

Major companies operating in the hemolysis detection devices market are focusing on developing innovative products such as point-of-care blood gas analyzers with hemolysis detection to enable rapid, accurate, and bedside detection of hemolysis, improving clinical decision-making and patient care. A point-of-care blood gas analyzer with hemolysis detection is a portable diagnostic system that assesses essential blood parameters at the bedside while detecting sample hemolysis that supports fast and reliable clinical decisions by enhancing test accuracy and minimizing errors resulting from red blood cell breakdown. For instance, in July 2024, Werfen S.A., a Spain-based diagnostics company, introduced the GEM Premier 7000 with intelligent quality management 3 (iQM3), designed to address key challenges in point-of-care blood gas testing. It combines patented acoustofluidic technology and photometric determination to detect hemolysis within 45 seconds, ensuring accurate potassium and other blood gas measurements. The system features real-time, automated quality checks for hemolysis, micro-clots, bubbles, and lipemia, along with a comprehensive test menu including pH, electrolytes, and CO-oximetry, making it ideal for enhancing patient safety, clinical decision-making, and workflow efficiency in critical care settings.

What Are Latest Mergers And Acquisitions In The Hemolysis Detection Devices Market?

In March 2025, Advanced Instruments LLC, a US-based manufacturing company, acquired Nova Biomedical Corp. for $2.2 billion. With this acquisition, Advanced Instruments aims to expand its portfolio of clinical and life science testing solutions, enhancing capabilities in blood gas, electrolyte, and chemistry analysis for hospitals, laboratories, and research institutions. Nova Biomedical Corp. is a US-based medical device company that produces critical care blood gas analyzers, which measure hemoglobin (Hb) and hematocrit (Hct) to detect hemolysis-related issues in whole blood samples.

Regional Insights

North America was the largest region in the hemolysis detection devices market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Hemolysis Detection Devices Market?

The hemolysis detection devices market consists of sales of hemolysis QC analyzers, serum indices controls, and photometric hemolysis detection readers and test kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data And Analysis Are Included In The Hemolysis Detection Devices Market Report 2026?

The hemolysis detection devices market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the hemolysis detection devices industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.